West Pharma (WST) Tops Q2 EPS by 1c; Lowers Top End of EPS Guidance

West Pharma (NYSE: WST) reported Q2 EPS of $0.66, $0.01 better than the analyst estimate of $0.65. Revenue for the quarter came in at $397.6 million versus the consensus estimate of $406 million.

Revising full-year 2017 sales and adjusted-diluted EPS guidance. Full-year 2017 sales guidance is expected to be in a range between $1.585 billion and $1.600 billion, compared to the prior guidance range between $1.585 billion and $1.610 billion. Full-year 2017 adjusted-diluted EPS guidance is expected to be in a range between $2.66 and $2.73, compared to the prior guidance range between $2.66 and $2.78. Both current and prior guidance ranges include the favorable impact from tax-related benefits associated with share-based payment transactions

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown